Pfizer ROA 2010-2022 | PFE

Current and historical return on assets (ROA) values for Pfizer (PFE) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Pfizer ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $29.31B $195.29B 15.85%
2022-03-31 $24.97B $183.84B 13.98%
2021-12-31 $21.98B $181.48B 12.75%
2021-09-30 $19.43B $179.19B 11.74%
2021-06-30 $12.76B $169.92B 7.71%
2021-03-31 $10.68B $158.82B 6.38%
2020-12-31 $9.16B $154.23B 5.41%
2020-09-30 $7.73B $178.98B 4.48%
2020-06-30 $13.94B $177.93B 8.17%
2020-03-31 $15.50B $166.34B 9.38%
2019-12-31 $16.03B $167.59B 9.87%
2019-09-30 $16.22B $170.45B 10.11%
2019-06-30 $12.65B $156.20B 7.92%
2019-03-31 $11.48B $155.42B 7.09%
2018-12-31 $11.15B $159.42B 6.79%
2018-09-30 $23.82B $167.84B 14.24%
2018-06-30 $22.55B $164.98B 13.39%
2018-03-31 $21.75B $164.61B 12.85%
2017-12-31 $21.31B $171.80B 12.51%
2017-09-30 $9.81B $172.15B 5.76%
2017-06-30 $8.32B $168.56B 4.84%
2017-03-31 $7.30B $168.78B 4.23%
2016-12-31 $7.22B $171.62B 4.22%
2016-09-30 $6.27B $178.43B 3.69%
2016-06-30 $7.04B $170.66B 4.19%
2016-03-31 $7.62B $162.93B 4.61%
2015-12-31 $6.96B $167.38B 4.22%
2015-09-30 $8.36B $170.87B 5.07%
2015-06-30 $8.90B $160.88B 5.39%
2015-03-31 $9.18B $160.64B 5.46%
2014-12-31 $9.14B $167.57B 5.35%
2014-09-30 $10.48B $171.36B 6.09%
2014-06-30 $10.40B $172.61B 6.01%
2014-03-31 $21.58B $171.81B 12.35%
2013-12-31 $22.00B $172.10B 12.32%
2013-09-30 $25.75B $175.52B 14.15%
2013-06-30 $26.37B $179.34B 14.35%
2013-03-31 $15.53B $187.40B 8.41%
2012-12-31 $14.57B $185.80B 7.91%
2012-09-30 $9.69B $182.60B 5.25%
2012-06-30 $10.22B $182.84B 5.43%
2012-03-31 $9.58B $185.68B 5.00%
2011-12-31 $10.01B $188.00B 5.17%
2011-09-30 $11.46B $196.13B 5.86%
2011-06-30 $8.59B $195.90B 4.42%
2011-03-31 $8.45B $194.96B 4.38%
2010-12-31 $8.26B $195.01B 4.27%
2010-09-30 $6.13B $191.42B 3.10%
2010-06-30 $8.15B $191.07B 4.40%
2010-03-31 $7.93B $195.11B 4.61%
2009-12-31 $8.64B $212.95B 5.60%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $245.597B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $429.503B 16.35
Eli Lilly (LLY) United States $307.239B 38.96
AbbVie (ABBV) United States $237.296B 10.08
Novo Nordisk (NVO) Denmark $225.460B 29.74
Merck (MRK) United States $218.166B 11.39
Novartis AG (NVS) Switzerland $168.180B 12.40